Base editing utilizes enzymes to modify single amino acids at the most foundational unit of DNA, called a base.

Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...

Sickle cell disease research news: STAT looks at new CRISPR-based treatment possibilities, and asks when sickle cell gene therapies will become widely available. For more on Oxbryta, Adakveo ...

It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science Foundation’s Faculty Early Career Development Program (CAREER) for ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex could receive roughly $100 million in top-line sales. Unfortunately, CRISPR ...

MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.